424 related articles for article (PubMed ID: 29573031)
1. A systematic review of adverse events of rifapentine and isoniazid compared to other treatments for latent tuberculosis infection.
Pease C; Hutton B; Yazdi F; Wolfe D; Hamel C; Barbeau P; Skidmore B; Alvarez GG
Pharmacoepidemiol Drug Saf; 2018 Jun; 27(6):557-566. PubMed ID: 29573031
[TBL] [Abstract][Full Text] [Related]
2. Twelve-Week Rifapentine Plus Isoniazid Versus 9-Month Isoniazid for the Treatment of Latent Tuberculosis in Renal Transplant Candidates.
Simkins J; Abbo LM; Camargo JF; Rosa R; Morris MI
Transplantation; 2017 Jun; 101(6):1468-1472. PubMed ID: 27548035
[TBL] [Abstract][Full Text] [Related]
3. Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV-negative people at risk of active TB.
Sharma SK; Sharma A; Kadhiravan T; Tharyan P
Cochrane Database Syst Rev; 2013 Jul; 2013(7):CD007545. PubMed ID: 23828580
[TBL] [Abstract][Full Text] [Related]
4. Recommendations for use of an isoniazid-rifapentine regimen with direct observation to treat latent Mycobacterium tuberculosis infection.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2011 Dec; 60(48):1650-3. PubMed ID: 22157884
[TBL] [Abstract][Full Text] [Related]
5. Management of Latent Tuberculosis Infection Among Healthcare Workers: 10-Year Experience at a Single Center.
Arguello Perez E; Seo SK; Schneider WJ; Eisenstein C; Brown AE
Clin Infect Dis; 2017 Nov; 65(12):2105-2111. PubMed ID: 29020308
[TBL] [Abstract][Full Text] [Related]
6. Short-course isoniazid plus rifapentine directly observed therapy for latent tuberculosis in solid-organ transplant candidates.
de Castilla DL; Rakita RM; Spitters CE; Narita M; Jain R; Limaye AP
Transplantation; 2014 Jan; 97(2):206-11. PubMed ID: 24142036
[TBL] [Abstract][Full Text] [Related]
7. Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV-negative people at risk of active TB.
Sharma SK; Sharma A; Kadhiravan T; Tharyan P
Evid Based Child Health; 2014 Mar; 9(1):169-294. PubMed ID: 25404581
[TBL] [Abstract][Full Text] [Related]
8. Treatment of latent tuberculosis infection: An update.
Lobue P; Menzies D
Respirology; 2010 May; 15(4):603-22. PubMed ID: 20409026
[TBL] [Abstract][Full Text] [Related]
9. An open label, randomised controlled trial of rifapentine versus rifampicin based short course regimens for the treatment of latent tuberculosis in England: the HALT LTBI pilot study.
Surey J; Stagg HR; Yates TA; Lipman M; White PJ; Charlett A; Muñoz L; Gosce L; Rangaka MX; Francis M; Hack V; Kunst H; Abubakar I
BMC Infect Dis; 2021 Jan; 21(1):90. PubMed ID: 33478428
[TBL] [Abstract][Full Text] [Related]
10. Impacts of 12-dose regimen for latent tuberculosis infection: Treatment completion rate and cost-effectiveness in Taiwan.
Huang YW; Yang SF; Yeh YP; Tsao TC; Tsao SM
Medicine (Baltimore); 2016 Aug; 95(34):e4126. PubMed ID: 27559940
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and completion rates of rifapentine and isoniazid (3HP) compared to other treatment regimens for latent tuberculosis infection: a systematic review with network meta-analyses.
Pease C; Hutton B; Yazdi F; Wolfe D; Hamel C; Quach P; Skidmore B; Moher D; Alvarez GG
BMC Infect Dis; 2017 Apr; 17(1):265. PubMed ID: 28399802
[TBL] [Abstract][Full Text] [Related]
12. Three months of rifapentine and isoniazid for latent tuberculosis infection in hemodialysis patients: High rates of adverse events.
Lin SY; Chiu YW; Lu PL; Hwang SJ; Chen TC; Hsieh MH; Chen YH
J Microbiol Immunol Infect; 2019 Feb; 52(1):158-162. PubMed ID: 29907535
[TBL] [Abstract][Full Text] [Related]
13. Use of Rifapentine and Isoniazid Directly Observed Therapy for the Treatment of Latent Tuberculosis Infection in a Military Clinic.
Jinbo J; Lustik M; West GF; Kloetzel M
Mil Med; 2017 Sep; 182(9):e2024-e2029. PubMed ID: 28885972
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of 3 Months of Once-Weekly Rifapentine and Isoniazid for Latent Tuberculosis Infection.
Walker RE; Bass S; Srinivas P; Miranda C; Johnson L; Pallotta AM
Ann Pharmacother; 2020 May; 54(5):457-463. PubMed ID: 31729245
[No Abstract] [Full Text] [Related]
15. Flu-like and Other Systemic Drug Reactions Among Persons Receiving Weekly Rifapentine Plus Isoniazid or Daily Isoniazid for Treatment of Latent Tuberculosis Infection in the PREVENT Tuberculosis Study.
Sterling TR; Moro RN; Borisov AS; Phillips E; Shepherd G; Adkinson NF; Weis S; Ho C; Villarino ME;
Clin Infect Dis; 2015 Aug; 61(4):527-35. PubMed ID: 25904367
[TBL] [Abstract][Full Text] [Related]
16. Self-administered Versus Directly Observed Once-Weekly Isoniazid and Rifapentine Treatment of Latent Tuberculosis Infection: A Randomized Trial.
Belknap R; Holland D; Feng PJ; Millet JP; Caylà JA; Martinson NA; Wright A; Chen MP; Moro RN; Scott NA; Arevalo B; Miró JM; Villarino ME; Weiner M; Borisov AS;
Ann Intern Med; 2017 Nov; 167(10):689-697. PubMed ID: 29114781
[TBL] [Abstract][Full Text] [Related]
17. Three months of weekly rifapentine plus isoniazid is less hepatotoxic than nine months of daily isoniazid for LTBI.
Bliven-Sizemore EE; Sterling TR; Shang N; Benator D; Schwartzman K; Reves R; Drobeniuc J; Bock N; Villarino ME;
Int J Tuberc Lung Dis; 2015 Sep; 19(9):1039-44, i-v. PubMed ID: 26260821
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of weekly rifapentine and isoniazid for tuberculosis prevention in Chinese silicosis patients: a randomized controlled trial.
Ruan QL; Huang XT; Yang QL; Liu XF; Wu J; Pan KC; Shen YJ; Cai LM; Ling Q; Jiang T; Hong JJ; Wang XD; Ma CL; Peng GQ; Wang XZ; Mao JC; Wu TZ; Lin MY; Shao LY; Zhang WH
Clin Microbiol Infect; 2021 Apr; 27(4):576-582. PubMed ID: 32553881
[TBL] [Abstract][Full Text] [Related]
19. Twelve-dose weekly rifapentine plus isoniazid for latent tuberculosis infection: A multicentre randomised controlled trial in Taiwan.
Sun HY; Huang YW; Huang WC; Chang LY; Chan PC; Chuang YC; Ruan SY; Wang JY; Wang JT
Tuberculosis (Edinb); 2018 Jul; 111():121-126. PubMed ID: 30029896
[TBL] [Abstract][Full Text] [Related]
20. Updates in the Treatment of Active and Latent Tuberculosis.
Haas MK; Belknap RW
Semin Respir Crit Care Med; 2018 Jun; 39(3):297-309. PubMed ID: 30071545
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
